Displaying drugs 6326 - 6350 of 7407 in total
Nolatrexed
Nolatrexed is under investigation in clinical trial NCT00012324 (Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer).
Investigational
Matched Iupac: … 2-amino-6-methyl-5-(pyridin-4-ylsulfanyl)-3,4-dihydroquinazolin-4-one …
Clorexolone
Experimental
Matched Iupac: … 6-chloro-2-cyclohexyl-3-oxo-2,3-dihydro-1H-isoindole-5-sulfonamide …
Emopamil
Prevents renal injury after warm & cold ischemia.
Experimental
Matched Iupac: … 5-[methyl(2-phenylethyl)amino]-2-phenyl-2-(propan-2-yl)pentanenitrile …
Vercirnon
Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD. It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786).
Investigational
Matched Iupac: … 4-[2-(4-tert-butylbenzenesulfonamido)-5-chlorobenzoyl]pyridin-1-ium-1-olate …
Chromium histidinate
Investigational
Matched Iupac: … chromium(3+) tris((2S)-2-amino-3-(1H-imidazol-5-yl)propanoate) …
L-N(omega)-Nitroarginine-2,4-L-diaminobutyric amide
Experimental
Matched Iupac: … (2S)-2-amino-N-[(1S)-3-amino-1-carbamoylpropyl]-5-(N'-nitrocarbamimidamido)pentanamide …
Tolrestat
Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. It was sold under the tradename...
Withdrawn
Matched Iupac: … 2-{1-[6-methoxy-5-(trifluoromethyl)naphthalen-1-yl]-N-methylmethanethioamido}acetic acid …
7-Deaza-7-Aminomethyl-Guanine
Experimental
Matched Iupac: … 2-amino-5-(aminomethyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one …
O1-Methyl-4-Deoxy-4-Thio-Alpha-D-Glucose
Experimental
Matched Iupac: … (2S,3R,4R,5S,6R)-6-(hydroxymethyl)-2-methoxy-5-sulfanyloxane-3,4-diol …
N-acetyl-D-glucosamine-6-phosphate
Experimental
Matched Iupac: … {[(2R,3S,4R,5R)-5-acetamido-3,4,6-trihydroxyoxan-2-yl]methoxy}phosphonic acid …
Coelenteramide
Experimental
Matched Iupac: … N-[3-benzyl-5-(4-hydroxyphenyl)pyrazin-2-yl]-2-(4-hydroxyphenyl)acetamide …
MK-0354
MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.
Investigational
Matched Iupac: … 5-{1H,4H,5H,6H-cyclopenta[c]pyrazol-3-yl}-2H-1,2,3,4-tetrazole …
3,4-Methylenedioxy-N-isopropylamphetamine
MDI-P has demonstrated potent anti-HIV activity. MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF").
Investigational
Matched Iupac: … [1-(2H-1,3-benzodioxol-5-yl)propan-2-yl](propan-2-yl)amine …
Dextofisopam
Investigational
Matched Iupac: … (5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine …
UK-396,082
UK-396,082 has been used in trials studying the basic science of Safety, Phase 1, Toleration, Multiple Dose, and Pharmacokinetic.
Investigational
Matched Iupac: … (2S)-5-amino-2-[(1-propyl-1H-imidazol-4-yl)methyl]pentanoic acid …
Losmapimod
Losmapimod has been investigated for the prevention of Chronic Obstructive Pulmonary Disease.
Investigational
Matched Iupac: … 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide …
SC-236
SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) that has been studied in cancer therapy , lower back pain , and inflammation , , , .
Experimental
Investigational
Matched Iupac: … 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide …
Azemiglitazone
Azemiglitazone is under investigation in clinical trial NCT01280695 (A Randomized, Double-blind, Comparator- and Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients).
Investigational
Matched Iupac: … 5-({4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione …
Metadoxine
Experimental
Matched Iupac: … (2S)-5-oxopyrrolidine-2-carboxylic acid; 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol …
Dideoxyadenosine
Investigational
Matched Iupac: … [(2S,5R)-5-(6-amino-9H-purin-9-yl)oxolan-2-yl]methanol …
Bilh 434
Experimental
Matched Iupac: … (2R,3'R,4'S,5'R)-5'-(3,4-dichlorophenyl)-6-methyl-1,3-dioxo-4'-{[4-(1,2,3-thiadiazol-4-yl)phenyl]carbamoyl …
Tacalcitol
Experimental
Investigational
Matched Iupac: … (1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R,5R)-5-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden …
Berbamine
Investigational
Aclarubicin
Investigational
Matched Iupac: … methyl (1R,2R,4S)-4-{[(2R,4S,5S,6S)-4-(dimethylamino)-5-{[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-{[(2R,6S ... )-6-methyl-5-oxooxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-2-ethyl-2,5,7-trihydroxy-6,11-dioxo …
Displaying drugs 6326 - 6350 of 7407 in total